Skip Main Navigation
Editor's Choice
Hepatitis B viruses - Copyright: Science Photo Library Drug approval - Copyright: iStockPhoto Transitional-cell carcinoma - Copyright: Elsevier
Article
Leading Edge
Review
Hepatitis B virus and non-Hodgkin lymphoma: in a cohort study of more than half a million participants, Engels and colleagues investigated the association between chronic HBV infection and risk of non-Hodgkin lymphoma. Accelerated drug approval: the dilemma of balancing scientific evidence against access to the latest treatments. Urothelium: a review presents current second-line therapy and emerging drugs for transitional-cell carcinoma.
Journal cover
Sep 2010

Volume 11
Number 9
Pages 805 - 906
Latest Podcast
September issue highlights, including discussion of a possible association between hepatitis B infection and non-Hodgkin lymphoma in a Korean population.
(mp3, 5:14 mins, 4.79Mb)

Leading Edge

805
When the evidence is weak, caution should be applied
The Lancet Oncology
Full Text | PDF

Reflection and Reaction

806
HBV infection as a risk factor for non-Hodgkin lymphoma
Sook-Hyang Jeong
Full Text | PDF
807
Pathological complete response: still a relevant endpoint in rectal cancer?
Yu Jo Chua
Full Text | PDF
808
S-1 for advanced colorectal cancer: do we need another oral fluorouracil prodrug?
Hans-Joachim Schmoll
Full Text | PDF
809
Is there really a yin and yang to VEGF-targeted therapies?
Lee M Ellis, David A Reardon
Full Text | PDF
811
Does the existing standard of care increase glioblastoma energy metabolism?
Thomas N Seyfried, Laura M Shelton, Purna Mukherjee
Full Text | PDF
813
Expression of concern—validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial
David Collingridge
Full Text | PDF
814
Testicular haemangiomas and vascular malformations
Israel Fernandez-Pineda, Lalit Parida
Full Text | PDF
815
Safety of denosumab in giant-cell tumour of bone
David Thomas, Phillipe Carriere, Ira Jacobs
Full Text | PDF
815
Cyanine dyes in optical imaging of tumours
Chunmeng Shi, Chao Zhang, Yongping Su, Tianmin Cheng
Full Text | PDF
816
Regulation of circadian rhythms and hypothalamic-pituitary-adrenal axis: an overlooked interaction in cancer
Pasquale F Innominato, Oxana Palesh, Firdaus S Dhabhar, Francis Lévi, David Spiegel
Full Text | PDF
817
Angiotensin-receptor blockade, cancer, and concerns
Mark R Goldstein, Luca Mascitelli, Francesca Pezzetta
Full Text | PDF
818
Angiotensin-receptor blockade, cancer, and concerns
Michael Böhm, Ulrich Laufs, Michael Pfreundschuh
Full Text | PDF
819
Angiotensin-receptor blockade, cancer, and concerns
Peter A Meredith, Gordon T McInnes
Full Text | PDF
819
Angiotensin-receptor blockade, cancer, and concerns
Vivencio Barrios, Carlos Escobar
Full Text | PDF
820
Angiotensin-receptor blockade, cancer, and concerns
Stevo Julius, Sverre E Kjeldsen, Michael A Weber
Full Text | PDF
821
Angiotensin-receptor blockade, cancer, and concerns – Authors' reply
Ilke Sipahi, Daniel I Simon, James C Fang
Full Text | PDF

News

823
Foundation hospitals
Talha Burki
Full Text | PDF
824
NICE issues guidance on cancer of unknown primary
Norra MacReady
Full Text | PDF

Cancer and Society

825
H2Oil
Talha Burki
Full Text | PDF
826
When Cancer Crosses Disciplines
Lee Schwartzberg
Full Text | PDF

Articles

827
Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study
Eric A Engels, Eo Rin Cho, Sun Ha Jee
Summary | Full Text | PDF
835
Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data
Monique Maas, Patty J Nelemans, Vincenzo Valentini, Prajnan Das, Claus Rödel, Li-Jen Kuo, Felipe A Calvo, Julio García-Aguilar, Rob Glynne-Jones, Karin Haustermans, Mohammed Mohiuddin, Salvatore Pucciarelli, William Small, Javier Suárez, George Theodoropoulos, Sebastiano Biondo, Regina GH Beets-Tan, Geerard L Beets
Summary | Full Text | PDF
845
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
Gianluca Masi, Fotios Loupakis, Lisa Salvatore, Lorenzo Fornaro, Chiara Cremolini, Samanta Cupini, Andrea Ciarlo, Francesca Del Monte, Enrico Cortesi, Domenico Amoroso, Cristina Granetto, Gabriella Fontanini, Elisa Sensi, Cristiana Lupi, Michele Andreuccetti, Alfredo Falcone
Summary | Full Text | PDF
853
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
Kei Muro, Narikazu Boku, Yasuhiro Shimada, Akihito Tsuji, Shinichi Sameshima, Hideo Baba, Taroh Satoh, Tadamichi Denda, Kenji Ina, Tomohiro Nishina, Kensei Yamaguchi, Hiroya Takiuchi, Taito Esaki, Shinya Tokunaga, Hiroyuki Kuwano, Yoshito Komatsu, Masahiko Watanabe, Ichinosuke Hyodo, Satoshi Morita, Kenichi Sugihara
Summary | Full Text | PDF

Review

861
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
Guru Sonpavde, Cora N Sternberg, Jonathan E Rosenberg, Noah M Hahn, Matthew D Galsky, Nicholas J Vogelzang
Summary | Full Text | PDF
871
Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours
Patrick Beauchesne
Summary | Full Text | PDF
880
Genetic aberrations in paediatric acute leukaemias and implications for management of patients
Tomasz Szczepański, Christine J Harrison, Jacques JM van Dongen
Summary | Full Text | PDF
890
Effect of genome-wide association studies, direct-to-consumer genetic testing, and high-speed sequencing technologies on predictive genetic counselling for cancer risk
Michael R Speicher, Jochen B Geigl, Ian P Tomlinson
Summary | Full Text | PDF

Personal View

899
PET in women with high risk for breast or ovarian cancer
Einat Even-Sapir, Moshe Inbar
Summary | Full Text | PDF

From the Archives

906
The sentinel-node concept: a dramatic improvement in breast-cancer surgery
Paul Berveiller, Olivier Mir, Nicolas Veyrie, Emmanuel Barranger
Full Text | PDF